{
  "timestamp": "2025-12-23T17:26:42.331217",
  "api_base_url": "http://127.0.0.1:8000",
  "test_cases": 3,
  "passed": 2,
  "failed": 1,
  "results": [
    {
      "test_case": "Multiple Myeloma - KRAS G12D",
      "status": "PASSED",
      "validation": {
        "has_drugs": true,
        "drugs_count": 5,
        "has_insights": true,
        "has_spe_breakdown": true,
        "confidence_valid": true,
        "evidence_tier_valid": true,
        "top_drug_match": true,
        "errors": []
      },
      "elapsed_seconds": 109.967656,
      "top_drug": {
        "name": "MEK inhibitor",
        "moa": "MAPK downstream blockade",
        "efficacy_score": 0.64,
        "confidence": 0.53,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": null,
          "review_status": null,
          "prior": 0.0
        },
        "evidence_manifest": {
          "pubmed_query": "KRAS p.G12D multiple_myeloma",
          "citations": [],
          "clinvar": {
            "classification": null,
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.0,
          "chromatin": 0.622,
          "essentiality": 0.0,
          "regulatory": 0.0
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.000510871410369873,
            "percentile": 0.8
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.8,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      }
    },
    {
      "test_case": "Ovarian Cancer - MBD4+TP53",
      "status": "PASSED",
      "validation": {
        "has_drugs": true,
        "drugs_count": 6,
        "has_insights": true,
        "has_spe_breakdown": true,
        "confidence_valid": true,
        "evidence_tier_valid": true,
        "top_drug_match": true,
        "errors": []
      },
      "elapsed_seconds": 15.002022,
      "top_drug": {
        "name": "olaparib",
        "moa": "PARP inhibitor",
        "efficacy_score": 0.75,
        "confidence": 0.59,
        "evidence_tier": "consider",
        "badges": [
          "PathwayAligned"
        ],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "MBD4 p.Q346* ovarian_cancer",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.0,
          "chromatin": 0.577,
          "essentiality": 0.0,
          "regulatory": 0.0
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 1.0,
            "percentile": 1.0
          },
          {
            "type": "pathway",
            "percentile": 1.0,
            "breakdown": {
              "ras_mapk": 0.0,
              "tp53": 0.8
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": false
      }
    },
    {
      "test_case": "Melanoma - BRAF V600E",
      "status": "FAILED",
      "validation": {
        "has_drugs": true,
        "drugs_count": 5,
        "has_insights": true,
        "has_spe_breakdown": true,
        "confidence_valid": true,
        "evidence_tier_valid": true,
        "top_drug_match": false,
        "errors": [
          "Top drug 'PEMBROLIZUMAB' doesn't match expected keywords: ['BRAF', 'BRAF inhibitor']"
        ]
      },
      "elapsed_seconds": 10.107776,
      "top_drug": {
        "name": "pembrolizumab",
        "moa": "anti-PD-1",
        "efficacy_score": 0.0,
        "confidence": 0.565,
        "evidence_tier": "insufficient",
        "badges": [],
        "evidence_strength": 0.0,
        "citations": [],
        "citations_count": 0,
        "clinvar": {
          "classification": "pathogenic",
          "review_status": null,
          "prior": 0.05
        },
        "evidence_manifest": {
          "pubmed_query": "BRAF p.V600E melanoma",
          "citations": [],
          "clinvar": {
            "classification": "pathogenic",
            "review_status": null
          }
        },
        "insights": {
          "functionality": 0.0,
          "chromatin": 0.411,
          "essentiality": 0.0,
          "regulatory": 0.0
        },
        "rationale": [
          {
            "type": "sequence",
            "value": 0.0023391246795654297,
            "percentile": 0.9
          },
          {
            "type": "pathway",
            "percentile": 0.0,
            "breakdown": {
              "ras_mapk": 0.9,
              "tp53": 0.0
            }
          },
          {
            "type": "evidence",
            "strength": 0.0
          }
        ],
        "meets_evidence_gate": false,
        "insufficient_signal": true
      }
    }
  ]
}